Alex Rosen
Director/Board Member at Upstream Bio, Inc.
Profile
Alex Rosen is currently working as a Director at Upstream Bio, Inc. Prior to this, he worked as a Biotech Investor at Venrock Associates.
Mr. Rosen holds a doctorate degree from the University of Pennsylvania, an undergraduate degree from Princeton University, and an MBA from The Wharton School of the University of Pennsylvania.
Alex Rosen active positions
| Companies | Position | Start |
|---|---|---|
Upstream Bio, Inc.
 Upstream Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021. | Director/Board Member | 08/06/2023 |
Former positions of Alex Rosen
| Companies | Position | End |
|---|---|---|
Venrock Associates
 Venrock Associates Investment ManagersFinance Venrock Associates is an Independent Venture Capital firm founded in 1969. The firm is headquartered in Palo Alto. | Private Equity Investor | - |
Training of Alex Rosen
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
| University of Pennsylvania | Doctorate Degree |
| Princeton University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
Venrock Associates
Venrock Associates Investment ManagersFinance Venrock Associates is an Independent Venture Capital firm founded in 1969. The firm is headquartered in Palo Alto. | Finance |
Upstream Bio, Inc.
Upstream Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021. | Commercial Services |
- Stock Market
- Insiders
- Alex Rosen
